Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
BETAMETHASONE (BETAMETHASONE DIPROPIONATE)
MERCK CANADA INC
D07AC01
BETAMETHASONE
0.05%
CREAM
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%
TOPICAL
15/50GM
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0106299002; AHFS:
CANCELLED POST MARKET
2019-06-28
PRODUCT MONOGRAPH DIPROLENE ® Glycol OINTMENT/CREAM (betamethasone dipropionate 0.05% W/W) Topical Corticosteroid MERCK CANADA INC. DATE OF REVISION: 16750 route Transcanadienne Kirkland, QC Canada H9H 4M7 March 21, 2019 www.merck.ca Control: 223941 ® Schering-Plough Canada Inc. Used under license. * All other trademarks are the property of their respective owner(s). © 2011, 2019 Merck Canada Inc., a subsidiary of MERCK & CO., INC. All rights reserved. 2 PRODUCT MONOGRAPH NAME OF DRUG DIPROLENE ® Glycol Ointment/Cream Betamethasone Dipropionate 0.05% W/W PHARMACOLOGICAL CLASSIFICATION Topical corticosteroid ACTIONS DIPROLENE ® Glycol provides anti-inflammatory, antipruritic and vasoconstrictive effects. The propylene glycol components of the vehicle increase penetration and enhance the local effectiveness of betamethasone dipropionate. INDICATIONS AND CLINICAL USES DIPROLENE ® Glycol is indicated for the relief of the inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. CONTRAINDICATIONS DIPROLENE ® Glycol is contraindicated in viral diseases including vaccinia, varicella, herpes simplex, and fungal infections; also, tuberculosis of the skin. DIPROLENE ® products are contraindicated in those patients with a history of sensitivity reactions to betamethasone dipropionate, other corticosteroids or to any of the components of DIPROLENE ® products. WARNINGS Do not use in or near the eyes since DIPROLENE ® Glycol is not formulated for ophthalmic use. This product should not be used under occlusive dressing. 3 Any of the side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children. Pregnancy and lactation: Since safety of topical corticosteroid use in pregnant women has not been established, drugs of this class should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class shoul Կարդացեք ամբողջական փաստաթուղթը